Company: XAIR
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001641172-25-023243
Chunk: 77

Company: Beyond Air, Inc.
Filing Date: 2025-08-12
Form: 10-Q
Item: Part II, Item 8
Chunk 77
---
 experienced losses on these accounts, and management believes the Company is not exposed to significant risks on
such accounts. As of June 30, 2025, the Company had greater than $250,000 at United States financial institutions, less than A$250,000
at Australian financial institutions, greater than €100,000 at Irish financial institutions and also has funds on deposit in Israel.
Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition,
results of operations and cash flows.

The
following table is the reconciliation of the presentation and disclosure of cash, cash equivalents, marketable securities by major security
type, and restricted cash as shown on the Company’s condensed consolidated statements of cash flows:

 SCHEDULE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH 

    (in thousands) 
    June 30, 2025  
    March 31, 2025 
  
    Cash and cash equivalents 
    $4,976  
    $4,665 
  
    Restricted cash 
     163  
     231 
  
    Total cash, cash equivalents and restricted cash 
    $5,139  
    $4,896 
  
    Marketable securities: 

    Mutual funds 
     1,487  
     2,252 
  
    Total marketable securities 
    $1,487  
    $2,252 

    Total cash, cash equivalents, marketable securities and restricted cash 
    $6,626  
    $7,148 

All
marketable securities are A- or higher rated. No marketable securities have maturities greater than 12 months. All investments are level
1 investments.

    13

BEYOND
AIR, INC. AND SUBSIDIARIES

NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE
2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)

Research
and Development

Research
and development expenses are charged to the unaudited condensed consolidated statements of operations and comprehensive loss as incurred.
Research and development expenses include salaries, benefits, stock-based compensation and costs incurred by outside laboratories, manufacturers,
clinical research organizations, consultants, and accredited facilities in connection with preclinical studies and clinical trials. Research
and development expenses are partially offset by the benefit of tax incentive